Superior Nanoemulsion Technology Yields Better Products
Superior Nanoemulsion Production
Microfluidizer® processors are capable of producing extremely small nano-emulsions. If the formulation is well designed, the resulting nanoemulsion will have a very small droplet size and narrow distribution which is ideal for stability and filtration. Microfluidics diverse product portfolio offer lab machines that can process samples as small as 2 mL and our fixed geometry Interaction Chambers ensure that the process can be scaled up to hundreds of liters per hour on the production scale machines. Microfluidizer® processors are designed to be simple to use and clean with the option of conforming to cGMP requirements. Let us use our collective 90 years of applications development and machine engineering experience to help drive your product to market as quickly as possible.
Proven Processing Solutions
Vaccine Adjuvant Nanoemulsion Collaboration with the Infectious Disease Research Institute (IDRI)
Unrivaled Uniform Particle Size Reduction
Nanoemulsions with small particle sizes increase bioavailability and enable targeting (e.g., cancer drugs getting past the blood/brain barrier and inside cells). In manufacturing nanoemulsion vaccine adjuvants, we found that emulsions obtained from a Microfluidizer® processor were 18% – 55% smaller than the homogenized emulsions using the same energy input, while the standard deviations of the emulsions processed on a Microfluidizer® processor (0.1 – 2.6) were much lower than those of the homogenized emulsions (3.8 – 14.8).
- View a webinar recording with Dr. Yang Su, New Technology Manager at Microfluidics titled Creating Nanoparticles with Microfluidizer® High Shear Technology
- See a poster comparing the Microfluidizer® processor to a High Pressure Homogenizer for the professing of a vaccine adjuvant
- See an application note produced in conjunction with Corixa for sterile filtration of a nanoemulsion
Instability and phase separation of emulsions and suspensions are critical challenges faced by research and production teams, as most technologies cannot produce the particle size distribution necessary to reach product goals. To overcome these issues, Microfluidizer® processors use unique fixed-geometry interaction chambers to reduce particle sizes uniformly and to a level unmatched by other methods. This enables customers to optimize formulations for maximum stability, and to enjoy the cost efficiencies offered by products with a prolonged shelf life.
Compared to a homogenizer, the use of a Microfluidizer® processor usually allows customers to reduce the number of passes needed to reach particle size goals, and to simplify downstream processing steps as well, both of which have cost benefits. Pharmaceutical applications, such as vaccine adjuvants, are often nanoemulsions requiring sterile filtration, and uniformly reducing particles to less than 200 nm significantly reduces the required filter area.
- View a webinar recording describing a collaboration with Pall titled Production & Sterilization of a Pharmaceutical Nanoemulsion Using Filtration
- See a poster detailing the Pall sterile filtration collaboration and results
Scaleup is guaranteed, bringing cost benefits to production volumes.
Enhancements such as translucent appearances for food or cosmetics products are more efficiently attainable with Microfluidics.
Nanotechnology in Pharmaceutical Applications
Nanoemulsions are an increasingly important drug delivery mechanism, and Microfluidizer® technology is ideal in the formulation of sterile injectable, insoluble drugs. Microfluidizer® processor is able to overcome the limitations of solubility, stability and sterilization that are inherent in conventional emulsions. Here are a few more webinars that detail some nanotechnology for pharmaceutical applications.
- Theranostic Nanoemuslions for Inflammatory Diseases From Design to Scale Up & Beyond
- Nanoemulsions for CNS Delivery of Biological Therapeutics